NCT02186873 · BASELINE

Baseline characteristics

A Study of Golimumab in Participants With Active Ankylosing Spondylitis · Source last updated 2025-10-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
103
group Id
BG001
value
105
group Id
BG002
value
208
units
Participants

groups

description
Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.
id
BG000
title
Group 1: Placebo Then Golimumab
description
Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.
id
BG001
title
Group 2: Golimumab
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
102
group Id
BG001
value
105
group Id
BG002
value
207
title
Between 18 and 65 years
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
10.75
value
39.2
group Id
BG001
spread
10.11
value
38.4
group Id
BG002
spread
10.41
value
38.8
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
26
group Id
BG001
value
19
group Id
BG002
value
45
title
Female
measurements
group Id
BG000
value
77
group Id
BG001
value
86
group Id
BG002
value
163
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
2
title
Canada
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
5
group Id
BG002
value
8
title
Germany
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
3
group Id
BG002
value
6
title
Mexico
categories
measurements
group Id
BG000
value
38
group Id
BG001
value
30
group Id
BG002
value
68
title
Poland
categories
measurements
group Id
BG000
value
16
group Id
BG001
value
14
group Id
BG002
value
30
title
Russian Federation
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
10
group Id
BG002
value
18
title
South Korea
categories
measurements
group Id
BG000
value
25
group Id
BG001
value
34
group Id
BG002
value
59
title
Ukraine
categories
measurements
group Id
BG000
value
9
group Id
BG001
value
8
group Id
BG002
value
17
title
United States
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

Complete source fields

denoms

counts
group Id
BG000
value
103
group Id
BG001
value
105
group Id
BG002
value
208
units
Participants

groups

description
Participants received placebo intravenous (IV) infusions at Weeks 0, 4, and 12. At Week 16 participants were crossed over to golimumab and received IV golimumab 2 mg/kg infusions at Weeks 16, 20, and every 8 weeks (q8w) thereafter through Week 52.
id
BG000
title
Group 1: Placebo Then Golimumab
description
Participants received IV golimumab 2 mg/kg infusion at Weeks 0, 4 and then q8w thereafter through Week 52. Participants received a placebo infusion at Week 16 to maintain the treatment blind.
id
BG001
title
Group 2: Golimumab
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
<=18 years
measurements
group Id
BG000
value
102
group Id
BG001
value
105
group Id
BG002
value
207
title
Between 18 and 65 years
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
>=65 years
param Type
COUNT_OF_PARTICIPANTS
title
Age, Categorical
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
10.75
value
39.2
group Id
BG001
spread
10.11
value
38.4
group Id
BG002
spread
10.41
value
38.8
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
26
group Id
BG001
value
19
group Id
BG002
value
45
title
Female
measurements
group Id
BG000
value
77
group Id
BG001
value
86
group Id
BG002
value
163
title
Male
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
2
title
Canada
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
5
group Id
BG002
value
8
title
Germany
categories
measurements
group Id
BG000
value
3
group Id
BG001
value
3
group Id
BG002
value
6
title
Mexico
categories
measurements
group Id
BG000
value
38
group Id
BG001
value
30
group Id
BG002
value
68
title
Poland
categories
measurements
group Id
BG000
value
16
group Id
BG001
value
14
group Id
BG002
value
30
title
Russian Federation
categories
measurements
group Id
BG000
value
8
group Id
BG001
value
10
group Id
BG002
value
18
title
South Korea
categories
measurements
group Id
BG000
value
25
group Id
BG001
value
34
group Id
BG002
value
59
title
Ukraine
categories
measurements
group Id
BG000
value
9
group Id
BG001
value
8
group Id
BG002
value
17
title
United States
param Type
NUMBER
title
Region of Enrollment
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice